CLCN4: A Potential Drug Target and Biomarker (G1183)

Target Name: CLCN4

NCBI ID: G1183

CLCN4

CLCN4: A Potential Drug Target and Biomarker

CLCN4 (Carcinoma-associated cell adhesion molecule 4) is a protein that is expressed in various types of cancer, including breast, ovarian, and colorectal cancers. It is a member of the cell adhesion molecule (CAM) family, which includes proteins such as E-cadherin, N-cadherin, and vimentin. CLCN4 has been shown to be involved in several cellular processes, including cell adhesion, migration, and invasion.

Recent studies have suggested that CLCN4 may be a potential drug target in cancer treatment. One reason for this is that CLCN4 has been shown to be involved in several signaling pathways that are involved in cancer development. For example, CLCN4 has been shown to be involved in the TGF-β pathway, which is a well-established pathway that is involved in cancer development. This is because CLCN4 is a strong predictor of cancer poor prognosis, and has been shown to be associated with several negative outcomes in cancer patients, including poor outcomes in patients with breast and ovarian cancers.

Another reason for CLCN4 being considered as a potential drug target is its role in cancer stem cells (CSCs). CSCs are cancer cells that have the ability to self-renew and differentiate into multiple different types of cells in the body. CLCN4 has been shown to be involved in the regulation of CSCs, and has been shown to play a role in the development and maintenance of these cells. This suggests that CLCN4 may be a useful target for cancer stem cell therapies.

In addition to its role in cancer development and maintenance, CLCN4 has also been shown to be involved in the regulation of angiogenesis, which is the process by which new blood vessels are formed in the body. This is important because angiogenesis is a critical process that is involved in the development of many types of cancer, including blood cancers.

Another potential mechanism by which CLCN4 may be involved in cancer treatment is its role in cell signaling pathways. CLCN4 has been shown to be involved in several signaling pathways, including the PI3K/Akt signaling pathway, which is involved in cell signaling and is often disrupted in cancer. This suggests that CLCN4 may be a useful target for cancer therapies that target these signaling pathways.

In conclusion, CLCN4 is a protein that has been shown to be involved in several cellular processes that are involved in cancer development and maintenance. As a result, CLCN4 has been suggested as a potential drug target for cancer treatment. Further research is needed to fully understand the role of CLCN4 in cancer development and to determine the most effective treatments for this protein.

Protein Name: Chloride Voltage-gated Channel 4

Functions: Strongly outwardly rectifying, electrogenic H(+)/Cl(-)exchanger which mediates the exchange of chloride ions against protons (PubMed:18063579, PubMed:28972156, PubMed:23647072, PubMed:27550844, PubMed:25644381). The CLC channel family contains both chloride channels and proton-coupled anion transporters that exchange chloride or another anion for protons (PubMed:29845874). The presence of conserved gating glutamate residues is typical for family members that function as antiporters (PubMed:29845874)

The "CLCN4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CLCN4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets